Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men

What Was Tested

This randomized controlled trial paper looks at Kisspeptin-10.

To assess the effects of kisspeptin on human bone metabolism in vitro and in vivo.

Why It Was Studied

Osteoporosis results from disturbances in bone formation and resorption.

However, the effects of kisspeptin on human bone metabolism are currently unknown.

Who Took Part

The abstract describes 26 men taking part.

The age groups tagged for this paper are young adults and adults, men only.

Clinical study: Randomized, placebo-controlled, double-blind, 2-way crossover clinical study in 26 men investigating the effects of acute kisspeptin administration (90 minutes) on human bone metabolism, with blood sampling every 30 minutes to +90 minutes.

Cells for the in vitro study were from 12 male blood donors and 8 patients undergoing hip replacement surgery.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Kisspeptin-10 and who got the comparison, which limits bias.

Neither the men nor the staff measuring them knew who was on Kisspeptin-10, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Kisspeptin-10 group a baseline to be compared against.

In the crossover set-up each of the men took both Kisspeptin-10 and the comparison in turn, acting as their own control.

In vitro study: of Mono- and cocultures of human osteoblasts and osteoclasts treated with kisspeptin.

Twenty-six healthy eugonadal men (age 26.8 ± 5.8 years) were included in the clinical study.

The intervention was Kisspeptin (vs placebo) administration.

The main outcome measures were changes in bone parameters and turnover markers.

What Was Measured

PubMed files the paper under topics including Bone Resorption, Cell Differentiation, Kisspeptins, Osteoblasts, Osteocalcin, Osteogenesis and Osteoporosis.

Author keywords: bone metabolism and reproduction.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Kisspeptin-10 in 26 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Kisspeptin-10 compound page, all human trials.